buyNotable
Norbert W Bischofberger bought $3.1M of KRON
PRESIDENT & CEO at Kronos Bio, Inc.. 3,005,122 shares at an average of $1.04, traded Jun 10, 2024, filed Jun 12, 2024.
Conviction score
60Value
$3.1M
3,005,122 shares
Holdings after
7,375,616
+69% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$3.1M at market
- +10Relative to holdingsHoldings up 69%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-016563, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +1,378,901 | $0.88 | $1.2M | 5,749,395 | Jun 12, 2024 |
| Jun 11, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +744,308 | $1.09 | $815k | 6,493,703 | Jun 12, 2024 |
| Jun 12, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +881,913 | $1.24 | $1.1M | 7,375,616 | Jun 12, 2024 |
Related signals
Other insiders at Kronos Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | KRONsell Kronos Bio, Inc. | Deborah Knobelman President & Interim CEO | $22k 24,838 shares | -15% | |
| 54Moderate | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $734k 615,518 shares | +6% | |
| 30Weak | Kronos Bio, Inc. | Allison Frisbee SR VP, CORP OPERATIONS & LEGAL | $13k 12,105 shares | -6% | |
| 30Weak | Kronos Bio, Inc. | Charles Y Lin SR VP, RESEARCH & DEVELOPMENT | $13k 12,036 shares | -5% | |
| 30Weak | Kronos Bio, Inc. | Elizabeth A Olek SR VP, CLINICAL SCIENCE | $7,765 7,368 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $14k 12,009 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $8,718 7,366 shares | -3% | |
| 35Weak | Kronos Bio, Inc. | Barbara Kosacz COO & General Counsel | $13k 10,676 shares | -1% | |
| 23Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $23k 17,367 shares | -5% | |
| 23Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $13k 10,032 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.